ORAMED PHARMACEUTICALS INC.

ORMPSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1176309

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$1.3M	$2.7M	$2.7M	$2.7M	$2.7M
Cost of Revenue	—	—	—	—	$90.0K
Research and Development Expense	$9.0M	$27.6M	$21.0M	$10.2M	$13.5M
Operating Income (Loss)	-$15.8M	-$40.6M	-$24.2M	-$11.8M	-$14.6M
Interest Expense	—	$2.0M	—	—	—
Nonoperating Income (Expense)	$22.9M	$2.9M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$5.1M	-$37.7M	—	—	-$14.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$220.6M	$161.6M	$177.8M	$44.6M	$34.7M
Assets, Current	$162.6M	$157.1M	$147.9M	$40.5M	$33.3M
Cash and Cash Equivalents, at Carrying Value	—	$40.5M	—	$3.3M	$5.0M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Liabilities, Current	$53.2M	$5.7M	$7.4M	$4.5M	$5.3M
Long-term Debt	—	—	$25.0K	—	—
Accounts Payable, Current	$551.0K	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$10.3M	-$27.9M	-$21.2M	-$12.4M	-$12.9M
Net Cash Provided by (Used in) Investing Activities	-$73.0M	$30.2M	-$23.8M	$4.6M	$11.3M
Net Cash Provided by (Used in) Financing Activities	$52.0M	$10.8M	$102.9M	$23.8M	$23.8M
Payments to Acquire Property, Plant, and Equipment	$254.0K	$496.0K	$375.0K	$82.0K	$15.0K
Payments for Repurchase of Common Stock	$2.5M	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)